Alfred Lim | Director of Lab Research
Etcembly Ltd
Alfred is Director of Lab Research at Etcembly, where he leads the development of new TCR drug candidates from discovery through to preclinical characterization and translational development. He was previously Head of Discovery at Theolytics and was responsible for candidate optimisation and lead nomination across the different pipeline programs. Alfred trained in immunology at the MRC Laboratory of Molecular Biology, Cambridge and holds a PhD in Molecular Immunology from the University of Cambridge.
Appearances:
Festival of Biologics Day 2 @ 17:10
Designing Potent TCR-based T Cell Engagers for Cancer Immunotherapy with Generative AI
Etcembly is the first company to leverage generative AI to discover and engineer a T cell receptor (TCR) to picomolar affinity. We formatted our lead PRAME targeting molecule, ETC-101, into a trispecific T cell engager and demonstrated that ETC-101 specifically redirected T cell killing of PRAME-positive cancer cells only, while demonstrating a promising safety profile with no detectable off-target effects. Our data highlights the efficacy of ETC-101 as a novel drug candidate for the treatment of a wide range of PRAME-positive malignancies.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events